menu
    • menu
    [{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Not Applicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ChromaDex, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Totum-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ INAF"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TOTUM\u202263","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Amolyt Pharma","amount2":1.05,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":1.05,"dosageForm":"","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Amolyt Pharma \/ AstraZeneca"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amolyt Pharma

                            France arrow
                            World ADC London
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AstraZeneca Closes Acquisition of Amolyt Pharma

                            Details : Through the acquisition, AstraZeneca leverages the AZP-3601 (neboparatide), peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.

                            Product Name : AZP-3601

                            Product Type : Peptide

                            Upfront Cash : $800.0 million

                            July 15, 2024

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study...

                            Details : TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.

                            Product Name : TOTUM•63

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : INAF

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Condu...

                            Details : TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes, has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.

                            Product Name : Totum-63

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 29, 2022

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : INAF

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ChromaDex, Inc

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonat...

                            Details : ChromaDex has invested over $35 million in investigating and marketing NR as Niagen, which has received regulatory acceptance in the United States, Canada, the European Union, and Australia.

                            Product Name : Niagen

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2020

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EAS...

                            Details : EASD has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.

                            Product Name : Totum-63

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 21, 2020

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed

                            Valbiotis

                            France arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VALBIOTIS Announces the First Patient Visit in the International Phase II/III REVERSE-IT Clinical Study on TOT...

                            Details : The REVERSE-IT study will include 600 patients with fasting hyperglycemia ranging from prediabetes to untreated early stage Type 2 Diabetes. The study should confirm the efficacy of TOTUM-63 - at a dose of 5g/day for 6 months.

                            Product Name : Totum-63

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 15, 2020

                            Lead Product(s) : Totum-63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth